Examkin

Soru

Zorluk: ZorPharmacologic Interventions

A 6464-year-old male is evaluated in the ambulatory clinic for optimization of his medical regimen following a recent discharge for volume overload. An echocardiogram obtained last week demonstrated a left ventricular ejection fraction of 28%28\%. Past medical history is significant for essential hypertension and type 2 diabetes mellitus. He is currently euvolemic, reporting no orthopnea or peripheral edema. His only current medications are oral furosemide and metformin. Vital signs demonstrate a blood pressure of 135/82 mmHg135/82\text{ mmHg} and a heart rate of 76 /min76\text{ /min}. Laboratory studies reveal a serum potassium of 4.2 mEq/L4.2\text{ mEq/L}, a serum creatinine of 1.1 mg/dL1.1\text{ mg/dL}, and a hemoglobin A1c of 8.1%8.1\%. Which of the following medications should be simultaneously initiated to optimize this patient's long-term pharmacotherapy and reduce mortality? (Select all that apply)

  1. Oral sacubitril-valsartanCevap
  2. Oral metoprolol succinateCevap
  3. Oral dapagliflozinCevap
  4. D
    Oral pioglitazone
  5. E
    Oral verapamil

Cevap

The correct regimen includes oral sacubitril-valsartan, oral metoprolol succinate, and oral dapagliflozin.
The correct combination initiates the pillars of guideline-directed medical therapy for heart failure with reduced ejection fraction (HFrEF). In a euvolemic, stable patient with an ejection fraction of 28%, immediate initiation of an angiotensin receptor-neprilysin inhibitor (sacubitril-valsartan) and an evidence-based beta-blocker (metoprolol succinate, carvedilol, or bisoprolol) is essential to reduce mortality and reverse cardiac remodeling. Furthermore, the addition of an SGLT2 inhibitor like dapagliflozin is indicated for all HFrEF patients regardless of diabetes status, but it provides particularly high utility in this patient by simultaneously addressing his suboptimally controlled type 2 diabetes.

Adım Adım Çözüm

1
Identify the primary clinical condition and patient stability.
The patient has newly diagnosed heart failure with reduced ejection fraction (LVEF 28%) and is currently euvolemic and hemodynamically stable.
Establishing euvolemic status is required before initiating certain beta-blockers, and determining the low LVEF directs the specific classes of medications needed.
2
Determine the necessary foundational guideline-directed medical therapy (GDMT) for the identified condition.
Standard GDMT requires an ARNI (sacubitril-valsartan) or ACEi/ARB, an evidence-based beta-blocker (metoprolol succinate), an MRA, and an SGLT2 inhibitor.
These medication classes have proven mortality and morbidity benefits in patients with reduced ejection fraction.
3
Evaluate the patient's comorbidities and how they intersect with potential pharmacotherapy.
The patient has poorly controlled type 2 diabetes (A1c 8.1%). Dapagliflozin provides dual benefits for both heart failure and diabetes.
Selecting medications with overlapping benefits minimizes polypharmacy and maximizes therapeutic efficacy.
4
Rule out contraindicated medications often used for the patient's comorbidities.
Pioglitazone (for diabetes) and verapamil (for hypertension) must be avoided.
These drugs exacerbate heart failure through fluid retention (pioglitazone) and negative inotropy (verapamil).

Anahtar Kavram

Guideline-directed medical therapy for heart failure with reduced ejection fraction requires multiple simultaneous neurohormonal antagonists, while strictly avoiding contraindicated medications like thiazolidinediones and non-dihydropyridine calcium channel blockers.
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru